Future Targeted Therapy Approaches in NSCLC
Anne S. Tsao, MD, and Edward B. Garon, MD, MS, conclude their discussion with a look to the future of TROP2 and associated targeted therapy approaches in non–small cell lung cancer.
EP: 1.Overview of Non–Small Cell Lung Cancer
EP: 2.The Role of Biomarkers in NSCLC Treatment
EP: 3.NSCLC Treatment: Unmet Needs and Antibody-Drug Conjugates
EP: 4.The Role of TROP2 as a Biomarker in NSCLC
EP: 5.NSCLC: Preclinical Studies on TROP2 Expression
EP: 6.Lung Cancer Treatment: Antibody-Drug Conjugates
EP: 7.Clinical Trial Data on Sacituzumab Govitecan in NSCLC
EP: 8.EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in First-Line Metastatic NSCLC
EP: 9.Advanced NSCLC: TROPION-Lung02 and TROPION-Lung04
EP: 10.Antibody-Drug Conjugate Safety Profiles in NSCLC
EP: 11.Recent Data on Datopotamab Deruxtecan in NSCLC
EP: 12.NSCLC: Dato-DXd Combination Therapy
EP: 13.NSCLC: Role of ADCs and Ongoing EVOKE-01 and EVOKE-03 Studies
EP: 14.Progress and Unmet Needs in NSCLC Treatment
EP: 15.Future Targeted Therapy Approaches in NSCLC
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
